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Purpose
The purpose of this study was to evaluate the treatment outcomes of radiotherapy (RT) for
breast cancer with ipsilateral supraclavicular (SCL) and/or internal mammary (IMN) lymph
node involvement.
Materials and Methods
A total of 353 patients from 11 institutions were included. One hundred and thirty-six pati-
ents had SCL involvement, 148 had IMN involvement, and 69 had both. All patients received
neoadjuvant systemic therapy followed by breast-conserving surgery or mastectomy, and
postoperative RT to whole breast/chest wall. As for regional lymph node irradiation, SCL RT
was given to 344 patients, and IMN RT to 236 patients. The median RT dose was 50.4 Gy.
Results
The median follow-up duration was 61 months (range, 7 to 173 months). In-field progression
was present in SCL (n=20) and/or IMN (n=7). The 5-year disease-free survival (DFS) and
overall survival rates were 57.8% and 75.1%, respectively. On multivariate analysis, both
SCL/IMN involvement, number of axillary lymph node  4, triple-negative subtype, and mas-
tectomy were significant adverse prognosticators for DFS (p=0.022, p=0.001, p=0.001,
and p=0.004, respectively). Regarding the impact of regional nodal irradiation, SCL RT dose
 54 Gy was not associated with DFS (5-year rate, 52.9% vs. 50.9%; p=0.696) in SCL-
involved patients, and the receipt of IMN RT was not associated with DFS (5-year rate, 56.1%
vs. 78.1%; p=0.099) in IMN-involved patients.
Conclusion
Neoadjuvant chemotherapy followed by surgery and postoperative RT achieved an accept-
able in-field regional control rate in patients with SCL and/or IMN involvement. However, a
higher RT dose to SCL or IMN RT was not associated with the improved DFS in these pati-
ents.
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Introduction
Since the recent publication of randomized controlled trials
[1,2], elective regional nodal radiotherapy (RT) including
supraclavicular lymph nodes (SCL) and internal mammary
lymph nodes (IMN) has become the standard treatment in
the adjuvant RT for node-positive breast cancer. In the mean-
while, neoadjuvant systemic therapy (NST) followed by sur-
gery and postoperative RT is a widely accepted treatment for
breast cancer with clinically apparent SCL or IMN [3-5]. Ini-
tially involved nodal areas are usually included in the RT
field, but there are little data on the impact of regional nodal
RT in this setting.
Historically, SCL involvement presented as palpable dis-
ease, and the IMN involvement was confirmed after surgical
excision such as extended radical mastectomy. With the 
development of imaging technologies such as positron emis-
sion tomography–computed tomography (PET-CT), how-
ever, extra-axillary regional lymph nodes in locally advanced
breast cancer have been increasingly detected [6-8]. Despite
the possibility of over-diagnosis, non-palpable SCL and/or
clinically detected IMN involvement is becoming more and
more common, and more data on the treatment outcome in
this setting is needed.
In this study, we evaluated the treatment outcomes of NST
followed by surgery and postoperative RT for breast cancer
with SCL and/or IMN involvement and investigated the 




After institutional review board approval, a total of 353 
patients with involved SCL and/or IMN but without distant
metastases were included from 11 institutions between Jan-
uary 2000 and December 2013. SCL and/or IMN metastases
were defined as involvement on imaging studies including
PET-CT, magnetic resonance imaging (MRI) of the breast,
chest CT, and/or breast ultrasonography (US).
Overall, PET-CT was performed in 325 patients (92.1%),
MRI in 274 (77.6%), CT in 119 (33.7%), and US in 342 (96.9%).
Among patients with SCL involvement (n=205), SCL was 
observed in PET-CT (173 of 189), MRI (71 of 141), CT (41 of
76), and US (146 of 198). Meanwhile, IMN was observed in
PET-CT (184 of 205), MRI (134 of 187), CT (37 of 69), and US
(127 of 213) among 217 patients with IMN involvement. 
According to the number of imaging modalities, all four
modalities identified SCL in three patients, three modalities
in 71, two modalities in 75, and a single modality in 56, while
IMN was identified by all four modalities in three patients,
three modalities in 95, two modalities in 67, and a single
modality in 52. Pathological confirmation was done in 99 
patients for SCL and 59 patients for IMN.
2. Treatment
All patients received NST. Chemotherapeutic regimen was
adriamycin-based chemotherapy (n=60), taxane-based che-
motherapy (n=268), and others (n=18). Seven patients recei-
ved hormonal therapy and/or anti–human epidermal grow-
th factor receptor 2 (HER2) therapy without cytotoxic che-
motherapy.
With regard to surgical treatment for breast, mastectomy
was performed in 224 patients, breast-conserving surgery in
127, and no breast surgery in two due to occult breast cancer.
Axillary lymph node dissection was performed in 304 pati-
ents and sentinel lymph node biopsy in 49. Fifty-nine pati-
ents underwent SCL excision and 14 patients underwent
IMN excision.
Postoperative RT was given to breast/chest wall up to a
median dose of 50.4 Gy (range, 43.2 to 70 Gy). SCL RT was
given in 344 patients, and IMN RT in 236. The median dose
to SCL and IMN was 50.4 Gy (range, 45 to 70.4 Gy) and 50.4
Gy (range, 43.2 to 66 Gy), respectively.
One hundred and fifty patients received adjuvant chemo-
therapy: adriamycin-based chemotherapy in 22 patients, tax-
ane-based chemotherapy in 100, and others in 28. One hund-
red and ninety-one patients received hormonal therapy, and
111 patients received anti-HER2 therapy.
3. Statistical analysis
Local recurrences were defined as disease recurrences in
the ipsilateral breast or chest wall, and regional recurrences
as those in the ipsilateral axillary lymph node, SCL, and/or
IMN. Disease recurrences other than local and/or regional
recurrences were defined as distant metastases. The time 
between initial treatment and recurrence or last follow-up
was measured as disease-free survival (DFS). Overall sur-
vival (OS) was defined from the date of initial treatment to
the date of death from any cause or last follow-up. The actu-
arial survival rates were calculated by the Kaplan-Meier
method and compared using the log-rank test. On multivari-
ate analysis, Cox proportional-hazards model was applied.
Factors with p-value < 0.05 on univariate analysis were 
included in the multivariate analysis. A p < 0.05 was consid-
ered statistically significant. Differences in categorical vari-
ables were compared using the standard chi-square test or
Kyubo Kim, RNI for Supraclavicular and Internal Mammary LN
Fisher exact test. All statistical analyses were performed
using SPSS software (release 18.0.1. SPSS Inc., Chicago, IL).
4. Ethical statement
The institutional review board approved this study (appro-
val number: H-1612-095-815 at Seoul National University




The patient and tumor characteristics are summarized in
Table 1. The median age was 47 years (range, 23 to 84 years).
As for clinical T category, 188 patients had cT1-2, and 161
had cT3-4 disease. One hundred and thirty-six patients had
SCL involvement, 148 had IMN involvement, and 69 had
both. After NST, pathologic T categories were as follows:
ypT0-is in 66 patients, ypT1-2 in 216, and ypT3-4 in 71. The
number of involved axillary lymph nodes was 0 in 103 pati-
ents, 1-3 in 98, 4-9 in 90, and  10 in 62. Regarding the res-
ponse of SCL and IMN to NST, each 75.9% of patients show-
ed clinical complete remission (CR) on imaging. Hormonal
receptor was positive in 53.0% of patients, and HER2 posi-
tivity was observed in 37.4% of patients.
2. Outcomes and prognostic factors
The median duration of follow-up was 61 months (range,
7 to 173 months). There were 67 patients with loco-regional
recurrences and 140 patients with distant metastases. Among
loco-regional recurrences, 20 patients had isolated local 
recurrences, 23 isolated regional recurrences, and 24 local
and regional recurrences. The 5-year DFS and OS were 57.8%
and 75.1%, respectively (Fig. 1).
On univariate analysis, ypT category, extent of SCL and/or
IMN involvement, number of involved axillary lymph
nodes, histologic grade, lymphovascular invasion, molecular
Table 1. Patient and tumor characteristics 
Values are presented as median (range) or number (%).
IMN, internal mammary lymph node; SCL, supraclavicu-
lar lymph node; HER2, human epidermal growth factor
receptor 2; NST, neoadjuvant systemic therapy; CR, com-
plete remission.
Variable No. (%) (n=353)






IMN only 148 (41.9)




















SCL response to NST
Clinical CR 267 (75.6)
Clinical non-CR 72 (20.4)
Unknown 14 (4.0)
IMN response to NST
Clinical CR 268 (75.9)
Clinical non-CR 66 (18.7)
Unknown 19 (5.4)
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subtype, type of breast surgery, hormonal therapy, and anti-
HER2 therapy were significantly associated with DFS. On
multivariate analysis, both SCL and IMN involvement (haz-
ard ratio [HR], 1.568; 95% confidence interval [CI], 1.066 to
2.304; p=0.022), four or more involved axillary lymph nodes
(HR, 1.950; 95% CI, 1.323 to 2.875; p=0.001), triple-negative
subtype (HR, 2.626; 95% CI, 1.482 to 4.653; p=0.001), and mas-
tectomy (HR, 1.911; 95% CI, 1.224 to 2.984; p=0.004) were 
adverse prognostic factors for DFS (Table 2).
With regard to OS, ypT cateogry, extent of SCL and/or
IMN involvement, number of involved axillary lymph
nodes, histologic grade, molecular subtype, type of breast
surgery, hormonal therapy, and anti-HER2 therapy were sig-
nificant prognostic factors on univariate analysis. Among
these, both SCL and IMN involvement (HR, 1.818; 95% CI,
1.145 to 2.887; p=0.011), histologic grade 3 (HR, 1.647; 95%
DFS OS
Variable 5-Year p-value HR p-value 5-Year p-value HR p-value  
rate (univariate) (95% CI) (multivariate) rate (univariate) (95% CI) (multivariate)
Age (yr)
< 40 50.9 0.089 74.7 0.290
 40 60.3 75.3
ypT category
0-1 64.1 0.002 1 ( 0.543 80.1 0.004 1 ( 0.065
2-4 50.0 1.126 (0.768-1.652) 68.9 1.534 (0.974-2.414)
Nodal involvement
Both SCL/IMN 47.8 0.046 1.568 (1.066-2.304) 0.022 63.4 0.019 1.818 (1.145-2.887) 0.011
Others 60.3 1 ( 78.0 1 (
No. of axillary 
lymph nodes
0-3 72.1 < 0.001 1 ( 0.001 80.5 0.001 1 ( 0.354
 4 49.1 1.950 (1.323-2.875) 68.0 1.235 (0.791-1.928)
Histologic grade
1 or 2 61.8 0.007 1 ( 0.081 81.4 0.001 1 ( 0.025
3 50.0 1.362 (0.963-1.928) 64.8 1.647 (1.065-2.548)
Lymphovascular invasion
Absent 64.0 < 0.001 1 ( 0.108 73.7 0.570
Present 49.1 1.363 (0.934-1.989) 76.5
Molecular subtype
Triple-negative 39.0 < 0.001 2.626 (1.482-4.653) 0.001 58.6 < 0.001 3.311 (2.121-5.170) < 0.001
Others 63.9 1 ( 80.8 1 (
Breast surgery
BCS 71.7 < 0.001 1 ( 0.004 85.4 0.001 1 ( 0.002
Mastectomy 49.8 1.911 (1.224-2.984) 69.2 2.421 (1.393-4.207)
Postoperative 
chemotherapy
No 57.6 0.802 73.7 0.189
Yes 57.7 77.0
Hormonal therapy
No 49.2 < 0.001 1 ( 0.620 65.8 < 0.001 1 ( 0.350
Yes 65.1 0.884 (0.542-1.441) 83.0 0.760 (0.427-1.352)
Herceptin
No 54.2 0.042 1 ( 0.867 72.3 0.032 1 ( 0.270
Yes 65.5 0.960 (0.595-1.549) 81.0 0.687 (0.352-1.338)
DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; SCL, supraclavicular lymph node;
IMN, internal mammary lymph node; BCS, breast-conserving surgery.
Table 2. Univariate and multivariate analyses for DFS and OS
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CI, 1.065 to 2.548; p=0.025), triple-negative subtype (HR,
3.311; 95% CI, 2.121 to 5.170; p < 0.001), and mastectomy (HR,
2.421; 95% CI, 1.393 to 4.207; p=0.002) were independently
correlated with a worse OS on multivariate analysis (Table 2).
3. Patterns of SCL and IMN failure according to the treat-
ments
Among 205 patients with SCL involvement, 201 patients
received SCL RT. More patients failed in the SCL with the
higher RT dose to SCL  54 Gy, but the difference was not
statistically significant (13.9% vs. 7.4%, p=0.130). According
to the response of SCL to NST, significantly more SCL fail-
ures were observed with  54 Gy in patients failing to achieve
CR to NST (25.0% vs. 2.3%, p=0.005). When 59 patients 
undergoing SCL excision were excluded, there were no dif-
ferences in the crude SCL failure rates according to the dose
to the SCL (Table 3). Among those patients who underwent
SCL excision, 12 patients achieved CR to NST and 47 did not,
and five patients who failed to achieve CR experienced SCL
failures. Regarding four patients who did not receive SCL
RT, they achieved CR to NST and did not undergo SCL exci-
sion, and there were no SCL failures during follow-up.
One hundred and eighty-five of 217 patients with IMN 
involvement received IMN RT. As for IMN failure, there was
no significant difference according to the receipt of IMN RT
in patients with IMN involvement (3.8% vs. 9.4%, p=0.139).
Patients achieving CR to NST had more IMN failures when
IMN RT was not given, but the difference did not reach a sta-
tistical significance (13.0% vs. 2.8%, p=0.065). When 14 pati-
ents undergoing IMN excision were excluded, a similar
finding was observed (Table 4). Among those patients who
underwent IMN excision, two patients achieved CR to NST
and 12 did not, and no patient experienced IMN failure.
When a log-rank test was performed in 184 patients who did
not undergo IMN excision and whose response to NST was
available, the 5-year IMN failure-free survival rates were
96.9% and 90.9% in patients with and without IMN RT, res-
pectively (p=0.064) (Fig. 2).
Recurrence in SCL/Total
Total p-value
SCL RT  54 Gy SCL RT < 54 Gy
CR to NSTa) 3/45 (6.7) 6/70 (8.6) 9/115 (7.8) > 0.990
Non-CR to NSTa) 7/28 (25.0) 1/44 (2.3) 8/72 (11.1) 0.005
CR to NSTb) 3/41 (7.3) 6/62 (9.7) 9/103 (8.7) > 0.990
Non-CR to NSTb) 3/14 (21.4) 0/11 (0) 3/25 (12.0) 0.230
Total 11/79 (13.9) 9/122 (7.4) 20/201 (10.0) 0.130
Values are presented as number (%). SCL, supraclavicular lymph node; RT, radiotherapy; CR, complete remission; NST,
neoadjuvant systemic therapy. a)14 patients, whose response to NST was unavailable, were excluded, b)73 patients, whose
response to NST was unavailable and who underwent SCL excision, were excluded.
Table 3. Patterns of SCL failure among 201 SCL-involved patients receiving SCL RT
Recurrence in IMN/Total
Total p-value
IMN RT (+) IMN RT (–)
CR to NSTa) 3/109 (2.8) 3/23 (13.0) 6/132 (4.5) 0.065
Non-CR to NSTa) 4/60 (6.7) 0/6 (0) 4/66 (6.1) > 0.990
CR to NSTb) 3/107 (2.8) 3/23 (13.0) 6/130 (4.6) 0.068
Non-CR to NSTb) 4/48 (8.3) 0/6 (0) 4/54 (7.4) > 0.990
Total 7/185 (3.8) 3/32 (9.4) 10/217 (4.6) 0.169
Values are presented as number (%). IMN, internal mammary lymph node; RT, radiotherapy; CR, complete remission; NST,
neoadjuvant systemic therapy. a)19 patients, whose response to NST was unavailable, were excluded, b)33 patients, whose
response to NST was unavailable and who underwent IMN excision, were excluded.
Table 4. Patterns of IMN failure among 217 IMN-involved patients
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4. Subgroup analysis according to the involvement of SCL
or IMN
Within patients with SCL involvement (n=205), higher ypT
category, four or more involved axillary lymph nodes, his-
tologic grade 3, triple-negative subtype, clinical non-CR of
SCL to NST, mastectomy, and SCL excision were associated
with an inferior DFS on univariate analysis. However, the
SCL RT dose  54 Gy did not improve DFS (5-year rate, 52.9%
vs. 50.9%; p=0.696) (Fig. 3). On multivariate analysis, four or
more involved axillary lymph nodes (HR, 1.636; 95% CI,
1.020 to 2.621; p=0.041), histologic grade 3 (HR, 1.665; 95%
CI, 1.085 to 2.555; p=0.020), triple-negative subtype (HR,
2.181; 95% CI, 1.369 to 3.473; p=0.001), and mastectomy (HR,
1.867; 95% CI, 1.036 to 3.365; p=0.038) were significant prog-
nosticators predicting a worse DFS.
With regard to those patients with IMN involvement
(n=217), additional SCL involvement, four or more involved 
axillary lymph nodes, lymphovascular invasion, triple-neg-
ative subtype, mastectomy, and no hormonal therapy were
correlated with an inferior DFS on univariate analysis. How-
ever, the receipt of IMN RT did not impact on DFS (5-year
rate, 56.1% with IMN RT vs. 78.1% without IMN RT;
p=0.099) (Fig. 4). On multivariate analysis, additional SCL
involvement (HR, 1.663; 95% CI, 1.070 to 2.587; p=0.024), four
or more involved axillary lymph nodes (HR, 1.814; 95% CI,
1.098 to 2.998; p=0.020), triple-negative subtype (HR, 3.995;
95% CI, 2.106 to 7.579; p < 0.001), and mastectomy (HR, 2.409;
95% CI, 1.405 to 4.129; p=0.001) were significant adverse
prognosticators for DFS.
5. Impact of SCL or IMN excision on the outcomes
Among 205 patients with SCL involvement, 59 patients 
underwent SCL excision along with the breast and axillary
surgery. Among these, the response to NST was clinical CR
in 12 and non-CR in 47. All of them received SCL RT, and the
median dose was 50.4 Gy (range, 45 to 66 Gy). Regarding the
patterns of failure, there were 10 patients with local recur-
rences, nine with regional recurrences including five with
SCL recurrences, and 35 with distant metastases. The 5-year
DFS was 38.1%, significantly inferior to those without SCL
excision (57.5%, p=0.026). As mentioned earlier, however, the
significance of SCL excision disappeared on multivariate
analysis.
Fourteen of 217 patients with IMN involvement had IMN
excision. Among these, the response to NST was clinical CR
in two and non-CR in 12. All of them received IMN RT. There
were two patients with local recurrences, two with regional
Fig. 2.  Internal mammary lymph node (IMN) failure-free
survival curves in patients with IMN involvement who
did not undergo IMN excision and whose response to
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Fig. 3.  Disease-free survival curves according to the dose
to the supraclavicular lymph node (SCL) among those 
patients with SCL involvement (n=201). Four patients not
























Fig. 4.  Disease-free survival curves according to the recei-
pt of internal mammary lymph node (IMN) irradiation
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recurrences (one in axillary lymph node and the other in the
SCL), and five with distant metastases. The 5-year DFS was
56.3%, which was not significantly different from those with-
out IMN excision (59.6%, p=0.901).
Discussion
In our study, the outcomes of NST followed by surgery
and postoperative RT were analyzed in 353 breast cancer 
patients with SCL and/or IMN involvement which was 
detected on imaging studies. The SCL and/or IMN failures
were rare, and a higher SCL RT dose as well as the receipt of
IMN RT was not associated with a better control rate. DFS
and OS were comparable with the contemporary results, but
were not improved by a higher dose SCL RT and IMN RT.
As for the treatment for extra-axillary regional lymph
nodes in breast cancer, especially IMN, there have been a
number of historical reports to date [9]. However, extended
radical mastectomy has rarely been performed since several
randomized trials noted no survival benefit of such an aggre-
ssive treatment [10,11]. With regard to the management for
SCL, some institutions reported the outcomes of SCL exci-
sion along with breast surgery, but its benefit is not evident
until now [12,13]. Therefore, the involved SCL and/or IMN
is usually diagnosed clinically and treated by regional nodal
RT combined with systemic therapy.
Recently, especially with the development of imaging
studies, more data on the multidisciplinary treatment in this
setting are becoming available. Among these, Zhang et al. [5]
reviewed 809 patients with cN2-3 patients, and found that
112 patients (13.8%) had IMN involvement on PET-CT, MRI,
CT and/or US [5]. They also analyzed the outcomes of NST
followed by surgery and postoperative RT in these patients,
and 72.1% of IMN-involved patients achieved clinical CR on
imaging after NST. In the present study, SCL and/or IMN
involvement was determined via the same imaging studies,
and each 75.9% of patients with SCL and IMN involvement
achieved clinical CR to NST. The treatment outcomes were
also very similar, and the 5-year DFS and OS were 56% and
76% in the Zhang et al.’s study [5], and 57.8% and 75.1% in
our study, respectively. In addition, Noh et al. [14] also 
reported the treatment outcomes of SCL- and/or IMN-
involved breast cancer which was detected on imaging stud-
ies including PET-CT and MRI. When treated with NST fol-
lowed by surgery and postoperative RT, the 5-year DFS and
OS were 60.2% and 75.5%, respectively. These observations
suggest that despite of the advanced nodal disease, favorable
DFS and OS can be achieved when multimodality treatments
are given. However, these data should be interpreted with
caution, because the involvement of SCL and/or IMN might
be overestimated on imaging and those patients with occult
distant metastases could be excluded after more meticulous
imaging studies such as PET-CT compared with historical
controls. Compared with aforementioned studies, Huang et
al. [4] reported the relatively inferior DFS and OS, that is, 30%
and 47%, respectively, in SCL-involved breast cancer patients 
receiving multimodality treatments. In this study, SCL invol-
vement was presented as palpable disease in 77.5% of pati-
ents, and clinical CR rate to NST was only 49%. These find-
ings suggest that their population might have a higher tumor
burden. In addition, pathologic confirmation of IMN invol-
vement on fine-needle aspiration biopsy was reported to be
associated with an inferior progression-free survival com-
pared to those of clinically involved IMN on PET-CT [15].
Regarding the impact of regional nodal RT for SCL and/or
IMN, Park et al. [3] analyzed 55 patients with PET-detected
cN3 breast cancer who were treated with NST followed by
surgery and postoperative RT. The 5-year locoregional 
relapse-free survival, DFS, and OS were 80%, 60%, and 79%,
respectively. And, both the higher RT dose to SCL  55 Gy
and the receipt of IMN RT was not associated with better out-
comes. We also observed similar findings among 353 patients
from 11 institutions, that is, DFS was not improved by a
higher dose SCL RT or IMN RT. Although the receipt of IMN
RT was associated with a lower IMN failure rate even in pati-
ents achieving clinical CR to NST, the difference did not
reach statistical significance. Rather, more SCL failures were
observed with a higher SCL RT dose in patients failing to
achieve clinical CR to NST. The paradoxical dose-response
relationship could be explained that a higher RT dose might
be prescribed to a larger residual lesion after NST. However,
the major patterns of failure were distant metastases, and
therefore this finding might not be translated into a mean-
ingful DFS difference. In the aforementioned study by
Huang et al. [4], a higher SCL RT dose was prescribed to pati-
ents with non-CR to NST and was not associated with a bet-
ter SCL control. However, non-CR to NST was the indepen-
dent prognostic factor associated with an inferior DFS [4].
Considering the increase of treatment failures in those pati-
ents with non-CR to NST (S1 and S2 Tables), more intensified
systemic therapy should be incorporated to these patients.
The limitations of this study are as follows. First, there
might be potential biases which are the typical shortcomings
of retrospective studies. Performance of mastectomy was 
associated with an inferior DFS, which suggests that patients
with more advanced disease underwent mastectomy. Sec-
ond, the involvement of SCL and/or IMN was determined
on imaging studies, and therefore might be overestimated.
In some patients undergoing SCL and/or IMN excision or
biopsy, the pathologic confirmation was done, but it was not
a routine procedure in most institutions. However, the diag-
Cancer Res Treat. 2019;51(4):1500-1508
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nostic accuracy of SCL and/or IMN involvement by PET-CT
or US was reported to be about 80%-90% [7,8], and our pati-
ents showed positive findings on multiple imaging studies
in 72.2% for SCL involvement and 76.0% for IMN involve-
ment. Lastly, the extent of SCL and/or IMN involvement
was not specified. As mentioned earlier, the paradoxical
dose-response relationship between SCL RT dose and SCL
failure might be resulted from a higher tumor burden una-
vailable from the retrospective chart review. Despite these
limitations, our study represents one of the largest series on
the outcomes of multidisciplinary treatment for breast cancer
patients with SCL and/or IMN involvement.
In conclusion, NST followed by surgery and postoperative
RT achieved an acceptable in-field regional control rate in
patients with SCL and/or IMN involvement. However, a
higher SCL RT dose or IMN RT was not associated with the
improved DFS in these patients. SCL and/or IMN excision,
which was more frequently performed in patients with non-
CR to NST, achieved acceptable local control but did not 
improve DFS, either. Given the major patterns of failure were
distant metastases, more intensified systemic therapy should
be incorporated especially in those patients with non-CR to
NST.
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